MedTrace Logo

Proteasis Evaluation in COPD

NCT01713335 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 134

Last updated 2021-08-26

No results posted yet for this study

Summary

The aim of this study was to evaluate kallikreins and its substrate, CCN, in COPD patients. Kallikreins are a subgroup of serine proteases, enzymes which are able to cleave peptide bonds in proteins. Kallicrein profile is unkonwn in COPD. The investigators will assess Kallikrein 1 to 15 and CCN 1 to 6 in sputum of patients. Three groups of patients will be included: Healthy smoker subjects, stable COPD patients and COPD patients with acute exacerbation. Kallicrein levels in sputum will be compared in these groups.

Conditions

Sponsors & Collaborators

  • Institut National de la Santé Et de la Recherche Médicale, France

    lead OTHER_GOV

Principal Investigators

  • Laurent Guilleminault, MD · Service de Pneumologie, CHRU Tours, Tours, France

  • Valérie Gissot, MD · Centre d'Investigation Clinique, CHRU Tours, Tours, France

  • Antoine Guillon, MD · Service de Réanimation médicale, CHRU Tours, Tours, France

Eligibility

Min Age
50 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-10-18
Primary Completion
2017-04-30
Completion
2017-04-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01713335 on ClinicalTrials.gov